Robert Knight
Keine laufenden Positionen mehr
Profil
Robert Knight is currently the Chief Medical Officer at NexImmune, Inc. Prior to this, he was the Vice President-Clinical Development at Kite Pharma, Inc. from 2020 to 2021, the Vice President-Clinical Research at Sorrento Therapeutics, Inc. from 2017 to 2020, and the Corporate Vice President at Celgene Corp.
from 2001 to 2017.
Dr. Knight received his undergraduate degree from the US Military Academy and his doctorate degree from The State University of New York.
Ehemalige bekannte Positionen von Robert Knight
Unternehmen | Position | Ende |
---|---|---|
KITE PHARMA INC | Corporate Officer/Principal | 01.01.2021 |
SORRENTO THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01.05.2020 |
CELGENE | Corporate Officer/Principal | 01.06.2017 |
NEXIMMUNE, INC. | Chief Tech/Sci/R&D Officer | - |
Ausbildung von Robert Knight
US Military Academy | Undergraduate Degree |
The State University of New York | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
NEXIMMUNE, INC. | Health Technology |
SORRENTO THERAPEUTICS, INC. | Health Technology |
Private Unternehmen | 2 |
---|---|
Celgene Corp.
Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
Kite Pharma, Inc.
Kite Pharma, Inc. BiotechnologyHealth Technology Kite Pharma, Inc. engages in the the development and commercialization of cancer immunotherapy products. Its products include chimeric antigen receptor (CAR) and T cell receptor (TCR), which address both hematological and solid cancers. The company was founded by Arie S. Belldegrun, James S. Economou, and Joshua A. Kazam on 2009 and is headquartered in Santa Monica, CA. | Health Technology |